Tumor Biology

, Volume 37, Issue 4, pp 5193–5202 | Cite as

miR-198 targets SHMT1 to inhibit cell proliferation and enhance cell apoptosis in lung adenocarcinoma

  • Shujun Wu
  • Guojun ZhangEmail author
  • Ping Li
  • Shanshan Chen
  • Furui Zhang
  • Juan Li
  • Chenyang Jiang
  • Xiaonan Chen
  • Yuanyuan Wang
  • Yuwen Du
  • Qianqian Sun
  • Guoqiang ZhaoEmail author
Original Article


MiR-198 is involved in tumorigenesis, migration, invasion, and metastasis of various malignant cancers. However, the exact expression levels of miR-198 and the molecular mechanism underlying its role in lung adenocarcinoma require further exploration. In this study, quantitative real-time PCR was applied to study miR-198 and serine hydroxymethyltransferase 1 (SHMT1) expression in 47 paired lung adenocarcinoma tissues and adjacent nontumor lung tissues. Clinicopathological characters were analyzed. Pearson’s correlation analysis was used to detect the relationship between miR-198 and SHMT1 expression. The function of miR-198 was explored by measuring cell proliferation, cell apoptosis, and the cell-cycle in vitro and in vivo. The target gene of miR-198 was certified using dual luciferase report assay. We found that in lung adenocarcinoma, miR-198 was significantly downregulated and SHMT1 was inversely upregulated. A strong negative correlation was noticed between miR-198 and SHMT1 expression. Further analysis revealed that miR-198 expression was associated with TNM stage and lymph node metastasis. Upregulated miR-198 could inhibit cell proliferation, enhance cell apoptosis, and lead to cell-cycle arrest in lung adenocarcinoma, which showed a more effective alteration than SHMT1 siRNA. Moreover, we identified SHMT1 as a target gene of miR-198. In conclusion, miR-198 suppressed proliferation of lung adenocarcinoma cells both in vitro and in vivo by directly targeting SHMT1. miR-198 may be a potential therapeutic target for lung adenocarcinoma in the near future.


MiR-198 Serine hydroxymethyltransferase 1 Proliferation Apoptosis Lung adenocarcinoma 



The authors are grateful to all staff that have contributed to this study at the lab center. This study was financially supported by Henan’s Ministry of Health, China (no. 201401005).

Compliance with ethical standards

Conflicts of interest



  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics: 2015. CA Cancer J Clin. 2015;65:5–29.CrossRefPubMedGoogle Scholar
  2. 2.
    Jemal A, Bray F, Center MM. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMedGoogle Scholar
  3. 3.
    Travis WD. Pathology of lung cancer. Clin Chest Med. 2011;32:669–92.CrossRefPubMedGoogle Scholar
  4. 4.
    Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359:1367–80.CrossRefPubMedGoogle Scholar
  5. 5.
    Al-Farsi A, Ellis PM. Treatment paradigms for patients with metastatic non-small cell lung cancer, squamous lung cancer: first, second, and third-line. Front Oncol. 2014;4:157.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Palanichamy JK, Rao DS. miRNA dysregulation in cancer: towards a mechanistic understanding. Front Genet. 2014;5:54.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Senthil K, Venugopa Joy J, Tae-Hun K, Yong L, Si-Si W, et al. Liver fibrosis causes downregulation of miRNA-150 and miRNA-194 in hepatic stellate cells, and their overexpression causes decreased stellate cell activation. Am J Physiol Gastrointest Liver Physiol. 2010;298:G101–6.CrossRefGoogle Scholar
  8. 8.
    Kim VN, Nam JW. Genomics of microRNA. Trends Genet. 2006;22:165–73.CrossRefPubMedGoogle Scholar
  9. 9.
    Farazi TA, Spitzer JI, Tuschl T. miRNAs in human cancer. J Pathol. 2011;223:102–15.CrossRefPubMedGoogle Scholar
  10. 10.
    Tan S, Li R, Ding K, Lobie PE, Zhu T. miR-198 inhibits migration and invasion of hepatocellular carcinoma cells by targeting the HGF/c-MET pathway. FEBS Lett. 2011;585:2229–34.CrossRefPubMedGoogle Scholar
  11. 11.
    Wang M, Wang J, Kong X, Chen H, Wang Y, Qin M, et al. MiR-198 represses tumor growth and metastasis in colorectal cancer by targeting fucosyl transferase 8. Sci Rep. 2014;4:6145.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Ye L, Li S, Ye D, Yang D, Yue F, Guo Y, et al. Livin expression may be regulated by miR-198 in human prostate cancer cell lines. Eur J Cancer. 2013;49:734–40.CrossRefPubMedGoogle Scholar
  13. 13.
    Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006;9:189–98.CrossRefPubMedGoogle Scholar
  14. 14.
    Yang J, Zhao H, Yu X, Fan L. MicroRNA-198 inhibits proliferation and induces apoptosis of lung cancer cells via targeting FGFR1. J Cell Biochem. 2014;115:987–95.CrossRefPubMedGoogle Scholar
  15. 15.
    Anderson DD, Woeller CF, Chiang EP, Shane B, Stover PJ. Serine hydroxymethyltransferase anchors de novo thymidylate synthesis pathway to nuclear lamina for DNA synthesis. J Biol Chem. 2012;287:7051–62.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Paone A, Marani M, Fiascarelli A, Rinaldo S, Giardina G, Contestabile R, et al. SHMT1 knockdown induces apoptosis in lung cancer cells by causing uracil misincorporation. Cell Death Dis. 2014;5, e1525.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Xing RC, Zheng J, Zheng WH, Qin ZP, Liu W, Yao RC. Relevance of E-cadherin expression to EGFR-TKI molecular targeted therapy sensitivity/resistance and its clinical significance. Genet Mol Res. 2015;14:5785–92.CrossRefPubMedGoogle Scholar
  18. 18.
    Maemondo M, Inoue A, Kobayashi K. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. New Engl J Med. 2010;362:2380–88.CrossRefPubMedGoogle Scholar
  19. 19.
    Steuer CE, Khuri FR, Ramalingam SS. The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer. Cancer. 2015;121:E1–6.CrossRefPubMedGoogle Scholar
  20. 20.
    Chen Z, Liu X, Zhao J, Yang H, Teng X. Correlation of EGFR mutation and histological subtype according to the IASLC/ATS/ERS classification of lung adenocarcinoma. Int J Clin Exp Pathol. 2014;7:8039–45.PubMedPubMedCentralGoogle Scholar
  21. 21.
    Takeuchi S, Yano S. Clinical significance of epidermal growth factor receptor tyrosine kinase inhibitors: sensitivity and resistance. Respir Investig. 2014;52:348–56.CrossRefPubMedGoogle Scholar
  22. 22.
    Ellis PM, Coakley N, Feld R, Kuruvilla S, Ung YC. Use of the epidermal growth factor receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the treatment of non-small-cell lung cancer: a systematic review. Curr Oncol. 2015;22:e183–215.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Paiardini A, Fiascarelli A, Rinaldo S, Daidone F, Giardina G, Koes DR, et al. Screening and in vitro testing of antifolate inhibitors of human cytosolic serine hydroxymethyltransferase. ChemMedChem. 2015;10:490–7.CrossRefPubMedGoogle Scholar
  24. 24.
    Kim HM, Jung WH, Koo JS. Site-specific metabolic phenotypes in metastatic breast cancer. J Transl Med. 2014;12:354.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Zhang WC, Shyh-Chang N, Yang H, Rai A, Umashankar S, Ma S, et al. Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis. Cell. 2012;148:259–72.CrossRefPubMedGoogle Scholar
  26. 26.
    Vychytilova-Faltejskova P, Kiss I, Klusova S, Hlavsa J, Prochazka V, Kala Z, et al. MiR-21, miR-34a, miR-198 and miR-217 as diagnostic and prognostic biomarkers for chronic pancreatitis and pancreatic ductal adenocarcinoma. Diagn Pathol. 2015;10:38.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Andrea V, Tyler J. miRNAs and cancer: a little RNA goes a long way. Cell. 2009;136:586–91.CrossRefGoogle Scholar
  28. 28.
    Iorio MV, Croce CM. Causes and consequences of microRNA dysregulation. Cancer J. 2012;18:215–22.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Shujun Wu
    • 1
  • Guojun Zhang
    • 1
    Email author
  • Ping Li
    • 1
  • Shanshan Chen
    • 1
  • Furui Zhang
    • 1
  • Juan Li
    • 1
  • Chenyang Jiang
    • 2
  • Xiaonan Chen
    • 3
  • Yuanyuan Wang
    • 3
  • Yuwen Du
    • 3
  • Qianqian Sun
    • 3
  • Guoqiang Zhao
    • 3
    Email author
  1. 1.Department of Respiratory MedicineThe First Affiliated Hospital of Zhengzhou UniversityZhengzhouChina
  2. 2.Department of NeurologyThe First Affiliated Hospital of Zhengzhou UniversityZhengzhouChina
  3. 3.School of Basic Medical SciencesZhengzhou UniversityZhengzhouChina

Personalised recommendations